Microbiome Therapeutics Industry Research Report 2024
Summary
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Microbiome Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Microbiome Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Interxon
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- AOBiome
- C3 Jian
- Rebiotix
- MicroBiome Therapeutics LLC
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Symbiotix Biotherapies
- Osel
- Metabogen
- Upper GIT
- Lower GIT
- C. difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Orphan Drug
- Immuno-oncology
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Microbiome Therapeutics by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Upper GIT
2.2.3 Lower GIT
2.3 Microbiome Therapeutics by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 C. difficile Infection (CDI)
2.3.3 Inflammatory Bowel Disease (IBD)
2.3.4 Orphan Drug
2.3.5 Immuno-oncology
2.3.6 Others
2.4 Assumptions and Limitations
3 MICROBIOME THERAPEUTICS BREAKDOWN DATA BY TYPE
3.1 Global Microbiome Therapeutics Historic Market Size by Type (2019-2024)
3.2 Global Microbiome Therapeutics Forecasted Market Size by Type (2025-2030)
4 MICROBIOME THERAPEUTICS BREAKDOWN DATA BY APPLICATION
4.1 Global Microbiome Therapeutics Historic Market Size by Application (2019-2024)
4.2 Global Microbiome Therapeutics Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Microbiome Therapeutics Market Perspective (2019-2030)
5.2 Global Microbiome Therapeutics Growth Trends by Region
5.2.1 Global Microbiome Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Microbiome Therapeutics Historic Market Size by Region (2019-2024)
5.2.3 Microbiome Therapeutics Forecasted Market Size by Region (2025-2030)
5.3 Microbiome Therapeutics Market Dynamics
5.3.1 Microbiome Therapeutics Industry Trends
5.3.2 Microbiome Therapeutics Market Drivers
5.3.3 Microbiome Therapeutics Market Challenges
5.3.4 Microbiome Therapeutics Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Microbiome Therapeutics Players by Revenue
6.1.1 Global Top Microbiome Therapeutics Players by Revenue (2019-2024)
6.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2019-2024)
6.2 Global Microbiome Therapeutics Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Microbiome Therapeutics Head office and Area Served
6.4 Global Microbiome Therapeutics Players, Product Type & Application
6.5 Global Microbiome Therapeutics Players, Date of Enter into This Industry
6.6 Global Microbiome Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Microbiome Therapeutics Market Size (2019-2030)
7.2 North America Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Microbiome Therapeutics Market Size by Country (2019-2024)
7.4 North America Microbiome Therapeutics Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Microbiome Therapeutics Market Size (2019-2030)
8.2 Europe Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Microbiome Therapeutics Market Size by Country (2019-2024)
8.4 Europe Microbiome Therapeutics Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Microbiome Therapeutics Market Size (2019-2030)
9.2 Asia-Pacific Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Microbiome Therapeutics Market Size by Country (2019-2024)
9.4 Asia-Pacific Microbiome Therapeutics Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Microbiome Therapeutics Market Size (2019-2030)
10.2 Latin America Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Microbiome Therapeutics Market Size by Country (2019-2024)
10.4 Latin America Microbiome Therapeutics Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Microbiome Therapeutics Market Size (2019-2030)
11.2 Middle East & Africa Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Microbiome Therapeutics Market Size by Country (2019-2024)
11.4 Middle East & Africa Microbiome Therapeutics Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 Seres Therapeutics
12.1.1 Seres Therapeutics Company Information
12.1.2 Seres Therapeutics Business Overview
12.1.3 Seres Therapeutics Revenue in Microbiome Therapeutics Business (2019-2024)
12.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
12.1.5 Seres Therapeutics Recent Developments
12.2 Assembly Biosciences
12.2.1 Assembly Biosciences Company Information
12.2.2 Assembly Biosciences Business Overview
12.2.3 Assembly Biosciences Revenue in Microbiome Therapeutics Business (2019-2024)
12.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
12.2.5 Assembly Biosciences Recent Developments
12.3 Synthetic Biologics
12.3.1 Synthetic Biologics Company Information
12.3.2 Synthetic Biologics Business Overview
12.3.3 Synthetic Biologics Revenue in Microbiome Therapeutics Business (2019-2024)
12.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
12.3.5 Synthetic Biologics Recent Developments
12.4 Interxon
12.4.1 Interxon Company Information
12.4.2 Interxon Business Overview
12.4.3 Interxon Revenue in Microbiome Therapeutics Business (2019-2024)
12.4.4 Interxon Microbiome Therapeutics Product Portfolio
12.4.5 Interxon Recent Developments
12.5 PureTech
12.5.1 PureTech Company Information
12.5.2 PureTech Business Overview
12.5.3 PureTech Revenue in Microbiome Therapeutics Business (2019-2024)
12.5.4 PureTech Microbiome Therapeutics Product Portfolio
12.5.5 PureTech Recent Developments
12.6 Synlogic
12.6.1 Synlogic Company Information
12.6.2 Synlogic Business Overview
12.6.3 Synlogic Revenue in Microbiome Therapeutics Business (2019-2024)
12.6.4 Synlogic Microbiome Therapeutics Product Portfolio
12.6.5 Synlogic Recent Developments
12.7 Enterome BioScience
12.7.1 Enterome BioScience Company Information
12.7.2 Enterome BioScience Business Overview
12.7.3 Enterome BioScience Revenue in Microbiome Therapeutics Business (2019-2024)
12.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
12.7.5 Enterome BioScience Recent Developments
12.8 4D Pharma
12.8.1 4D Pharma Company Information
12.8.2 4D Pharma Business Overview
12.8.3 4D Pharma Revenue in Microbiome Therapeutics Business (2019-2024)
12.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
12.8.5 4D Pharma Recent Developments
12.9 Second Genome
12.9.1 Second Genome Company Information
12.9.2 Second Genome Business Overview
12.9.3 Second Genome Revenue in Microbiome Therapeutics Business (2019-2024)
12.9.4 Second Genome Microbiome Therapeutics Product Portfolio
12.9.5 Second Genome Recent Developments
12.10 AOBiome
12.10.1 AOBiome Company Information
12.10.2 AOBiome Business Overview
12.10.3 AOBiome Revenue in Microbiome Therapeutics Business (2019-2024)
12.10.4 AOBiome Microbiome Therapeutics Product Portfolio
12.10.5 AOBiome Recent Developments
12.11 C3 Jian
12.11.1 C3 Jian Company Information
12.11.2 C3 Jian Business Overview
12.11.3 C3 Jian Revenue in Microbiome Therapeutics Business (2019-2024)
12.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
12.11.5 C3 Jian Recent Developments
12.12 Rebiotix
12.12.1 Rebiotix Company Information
12.12.2 Rebiotix Business Overview
12.12.3 Rebiotix Revenue in Microbiome Therapeutics Business (2019-2024)
12.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
12.12.5 Rebiotix Recent Developments
12.13 MicroBiome Therapeutics LLC
12.13.1 MicroBiome Therapeutics LLC Company Information
12.13.2 MicroBiome Therapeutics LLC Business Overview
12.13.3 MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2019-2024)
12.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
12.13.5 MicroBiome Therapeutics LLC Recent Developments
12.14 Metabiomics
12.14.1 Metabiomics Company Information
12.14.2 Metabiomics Business Overview
12.14.3 Metabiomics Revenue in Microbiome Therapeutics Business (2019-2024)
12.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
12.14.5 Metabiomics Recent Developments
12.15 Ritter Pharmaceuticals
12.15.1 Ritter Pharmaceuticals Company Information
12.15.2 Ritter Pharmaceuticals Business Overview
12.15.3 Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2019-2024)
12.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
12.15.5 Ritter Pharmaceuticals Recent Developments
12.16 Symberix
12.16.1 Symberix Company Information
12.16.2 Symberix Business Overview
12.16.3 Symberix Revenue in Microbiome Therapeutics Business (2019-2024)
12.16.4 Symberix Microbiome Therapeutics Product Portfolio
12.16.5 Symberix Recent Developments
12.17 OpenBiome
12.17.1 OpenBiome Company Information
12.17.2 OpenBiome Business Overview
12.17.3 OpenBiome Revenue in Microbiome Therapeutics Business (2019-2024)
12.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
12.17.5 OpenBiome Recent Developments
12.18 Azitra
12.18.1 Azitra Company Information
12.18.2 Azitra Business Overview
12.18.3 Azitra Revenue in Microbiome Therapeutics Business (2019-2024)
12.18.4 Azitra Microbiome Therapeutics Product Portfolio
12.18.5 Azitra Recent Developments
12.19 Symbiotix Biotherapies
12.19.1 Symbiotix Biotherapies Company Information
12.19.2 Symbiotix Biotherapies Business Overview
12.19.3 Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2019-2024)
12.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
12.19.5 Symbiotix Biotherapies Recent Developments
12.20 Osel
12.20.1 Osel Company Information
12.20.2 Osel Business Overview
12.20.3 Osel Revenue in Microbiome Therapeutics Business (2019-2024)
12.20.4 Osel Microbiome Therapeutics Product Portfolio
12.20.5 Osel Recent Developments
12.21 Metabogen
12.21.1 Metabogen Company Information
12.21.2 Metabogen Business Overview
12.21.3 Metabogen Revenue in Microbiome Therapeutics Business (2019-2024)
12.21.4 Metabogen Microbiome Therapeutics Product Portfolio
12.21.5 Metabogen Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Microbiome Therapeutics by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Upper GIT
2.2.3 Lower GIT
2.3 Microbiome Therapeutics by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 C. difficile Infection (CDI)
2.3.3 Inflammatory Bowel Disease (IBD)
2.3.4 Orphan Drug
2.3.5 Immuno-oncology
2.3.6 Others
2.4 Assumptions and Limitations
3 MICROBIOME THERAPEUTICS BREAKDOWN DATA BY TYPE
3.1 Global Microbiome Therapeutics Historic Market Size by Type (2019-2024)
3.2 Global Microbiome Therapeutics Forecasted Market Size by Type (2025-2030)
4 MICROBIOME THERAPEUTICS BREAKDOWN DATA BY APPLICATION
4.1 Global Microbiome Therapeutics Historic Market Size by Application (2019-2024)
4.2 Global Microbiome Therapeutics Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Microbiome Therapeutics Market Perspective (2019-2030)
5.2 Global Microbiome Therapeutics Growth Trends by Region
5.2.1 Global Microbiome Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Microbiome Therapeutics Historic Market Size by Region (2019-2024)
5.2.3 Microbiome Therapeutics Forecasted Market Size by Region (2025-2030)
5.3 Microbiome Therapeutics Market Dynamics
5.3.1 Microbiome Therapeutics Industry Trends
5.3.2 Microbiome Therapeutics Market Drivers
5.3.3 Microbiome Therapeutics Market Challenges
5.3.4 Microbiome Therapeutics Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Microbiome Therapeutics Players by Revenue
6.1.1 Global Top Microbiome Therapeutics Players by Revenue (2019-2024)
6.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2019-2024)
6.2 Global Microbiome Therapeutics Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Microbiome Therapeutics Head office and Area Served
6.4 Global Microbiome Therapeutics Players, Product Type & Application
6.5 Global Microbiome Therapeutics Players, Date of Enter into This Industry
6.6 Global Microbiome Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Microbiome Therapeutics Market Size (2019-2030)
7.2 North America Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Microbiome Therapeutics Market Size by Country (2019-2024)
7.4 North America Microbiome Therapeutics Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Microbiome Therapeutics Market Size (2019-2030)
8.2 Europe Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Microbiome Therapeutics Market Size by Country (2019-2024)
8.4 Europe Microbiome Therapeutics Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Microbiome Therapeutics Market Size (2019-2030)
9.2 Asia-Pacific Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Microbiome Therapeutics Market Size by Country (2019-2024)
9.4 Asia-Pacific Microbiome Therapeutics Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Microbiome Therapeutics Market Size (2019-2030)
10.2 Latin America Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Microbiome Therapeutics Market Size by Country (2019-2024)
10.4 Latin America Microbiome Therapeutics Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Microbiome Therapeutics Market Size (2019-2030)
11.2 Middle East & Africa Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Microbiome Therapeutics Market Size by Country (2019-2024)
11.4 Middle East & Africa Microbiome Therapeutics Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 Seres Therapeutics
12.1.1 Seres Therapeutics Company Information
12.1.2 Seres Therapeutics Business Overview
12.1.3 Seres Therapeutics Revenue in Microbiome Therapeutics Business (2019-2024)
12.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
12.1.5 Seres Therapeutics Recent Developments
12.2 Assembly Biosciences
12.2.1 Assembly Biosciences Company Information
12.2.2 Assembly Biosciences Business Overview
12.2.3 Assembly Biosciences Revenue in Microbiome Therapeutics Business (2019-2024)
12.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
12.2.5 Assembly Biosciences Recent Developments
12.3 Synthetic Biologics
12.3.1 Synthetic Biologics Company Information
12.3.2 Synthetic Biologics Business Overview
12.3.3 Synthetic Biologics Revenue in Microbiome Therapeutics Business (2019-2024)
12.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
12.3.5 Synthetic Biologics Recent Developments
12.4 Interxon
12.4.1 Interxon Company Information
12.4.2 Interxon Business Overview
12.4.3 Interxon Revenue in Microbiome Therapeutics Business (2019-2024)
12.4.4 Interxon Microbiome Therapeutics Product Portfolio
12.4.5 Interxon Recent Developments
12.5 PureTech
12.5.1 PureTech Company Information
12.5.2 PureTech Business Overview
12.5.3 PureTech Revenue in Microbiome Therapeutics Business (2019-2024)
12.5.4 PureTech Microbiome Therapeutics Product Portfolio
12.5.5 PureTech Recent Developments
12.6 Synlogic
12.6.1 Synlogic Company Information
12.6.2 Synlogic Business Overview
12.6.3 Synlogic Revenue in Microbiome Therapeutics Business (2019-2024)
12.6.4 Synlogic Microbiome Therapeutics Product Portfolio
12.6.5 Synlogic Recent Developments
12.7 Enterome BioScience
12.7.1 Enterome BioScience Company Information
12.7.2 Enterome BioScience Business Overview
12.7.3 Enterome BioScience Revenue in Microbiome Therapeutics Business (2019-2024)
12.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
12.7.5 Enterome BioScience Recent Developments
12.8 4D Pharma
12.8.1 4D Pharma Company Information
12.8.2 4D Pharma Business Overview
12.8.3 4D Pharma Revenue in Microbiome Therapeutics Business (2019-2024)
12.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
12.8.5 4D Pharma Recent Developments
12.9 Second Genome
12.9.1 Second Genome Company Information
12.9.2 Second Genome Business Overview
12.9.3 Second Genome Revenue in Microbiome Therapeutics Business (2019-2024)
12.9.4 Second Genome Microbiome Therapeutics Product Portfolio
12.9.5 Second Genome Recent Developments
12.10 AOBiome
12.10.1 AOBiome Company Information
12.10.2 AOBiome Business Overview
12.10.3 AOBiome Revenue in Microbiome Therapeutics Business (2019-2024)
12.10.4 AOBiome Microbiome Therapeutics Product Portfolio
12.10.5 AOBiome Recent Developments
12.11 C3 Jian
12.11.1 C3 Jian Company Information
12.11.2 C3 Jian Business Overview
12.11.3 C3 Jian Revenue in Microbiome Therapeutics Business (2019-2024)
12.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
12.11.5 C3 Jian Recent Developments
12.12 Rebiotix
12.12.1 Rebiotix Company Information
12.12.2 Rebiotix Business Overview
12.12.3 Rebiotix Revenue in Microbiome Therapeutics Business (2019-2024)
12.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
12.12.5 Rebiotix Recent Developments
12.13 MicroBiome Therapeutics LLC
12.13.1 MicroBiome Therapeutics LLC Company Information
12.13.2 MicroBiome Therapeutics LLC Business Overview
12.13.3 MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2019-2024)
12.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
12.13.5 MicroBiome Therapeutics LLC Recent Developments
12.14 Metabiomics
12.14.1 Metabiomics Company Information
12.14.2 Metabiomics Business Overview
12.14.3 Metabiomics Revenue in Microbiome Therapeutics Business (2019-2024)
12.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
12.14.5 Metabiomics Recent Developments
12.15 Ritter Pharmaceuticals
12.15.1 Ritter Pharmaceuticals Company Information
12.15.2 Ritter Pharmaceuticals Business Overview
12.15.3 Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2019-2024)
12.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
12.15.5 Ritter Pharmaceuticals Recent Developments
12.16 Symberix
12.16.1 Symberix Company Information
12.16.2 Symberix Business Overview
12.16.3 Symberix Revenue in Microbiome Therapeutics Business (2019-2024)
12.16.4 Symberix Microbiome Therapeutics Product Portfolio
12.16.5 Symberix Recent Developments
12.17 OpenBiome
12.17.1 OpenBiome Company Information
12.17.2 OpenBiome Business Overview
12.17.3 OpenBiome Revenue in Microbiome Therapeutics Business (2019-2024)
12.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
12.17.5 OpenBiome Recent Developments
12.18 Azitra
12.18.1 Azitra Company Information
12.18.2 Azitra Business Overview
12.18.3 Azitra Revenue in Microbiome Therapeutics Business (2019-2024)
12.18.4 Azitra Microbiome Therapeutics Product Portfolio
12.18.5 Azitra Recent Developments
12.19 Symbiotix Biotherapies
12.19.1 Symbiotix Biotherapies Company Information
12.19.2 Symbiotix Biotherapies Business Overview
12.19.3 Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2019-2024)
12.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
12.19.5 Symbiotix Biotherapies Recent Developments
12.20 Osel
12.20.1 Osel Company Information
12.20.2 Osel Business Overview
12.20.3 Osel Revenue in Microbiome Therapeutics Business (2019-2024)
12.20.4 Osel Microbiome Therapeutics Product Portfolio
12.20.5 Osel Recent Developments
12.21 Metabogen
12.21.1 Metabogen Company Information
12.21.2 Metabogen Business Overview
12.21.3 Metabogen Revenue in Microbiome Therapeutics Business (2019-2024)
12.21.4 Metabogen Microbiome Therapeutics Product Portfolio
12.21.5 Metabogen Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Microbiome Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Microbiome Therapeutics Revenue Market Share by Type (2018-2023)
Table 7. Global Microbiome Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Microbiome Therapeutics Revenue Market Share by Type (2024-2029)
Table 9. Global Microbiome Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Microbiome Therapeutics Revenue Market Share by Application (2018-2023)
Table 11. Global Microbiome Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Microbiome Therapeutics Revenue Market Share by Application (2024-2029)
Table 13. Global Microbiome Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Microbiome Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Microbiome Therapeutics Market Share by Region (2018-2023)
Table 16. Global Microbiome Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Microbiome Therapeutics Market Share by Region (2024-2029)
Table 18. Microbiome Therapeutics Market Trends
Table 19. Microbiome Therapeutics Market Drivers
Table 20. Microbiome Therapeutics Market Challenges
Table 21. Microbiome Therapeutics Market Restraints
Table 22. Global Top Microbiome Therapeutics Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Microbiome Therapeutics Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Microbiome Therapeutics Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Microbiome Therapeutics, Headquarters and Area Served
Table 26. Global Microbiome Therapeutics Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Microbiome Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 45. Seres Therapeutics Company Detail
Table 46. Seres Therapeutics Business Overview
Table 47. Seres Therapeutics Microbiome Therapeutics Product
Table 48. Seres Therapeutics Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Seres Therapeutics Recent Development
Table 50. Assembly Biosciences Company Detail
Table 51. Assembly Biosciences Business Overview
Table 52. Assembly Biosciences Microbiome Therapeutics Product
Table 53. Assembly Biosciences Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 54. Assembly Biosciences Recent Development
Table 55. Synthetic Biologics Company Detail
Table 56. Synthetic Biologics Business Overview
Table 57. Synthetic Biologics Microbiome Therapeutics Product
Table 58. Synthetic Biologics Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Synthetic Biologics Recent Development
Table 60. Interxon Company Detail
Table 61. Interxon Business Overview
Table 62. Interxon Microbiome Therapeutics Product
Table 63. Interxon Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Interxon Recent Development
Table 65. PureTech Company Detail
Table 66. PureTech Business Overview
Table 67. PureTech Microbiome Therapeutics Product
Table 68. PureTech Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 69. PureTech Recent Development
Table 70. Synlogic Company Detail
Table 71. Synlogic Business Overview
Table 72. Synlogic Microbiome Therapeutics Product
Table 73. Synlogic Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Synlogic Recent Development
Table 75. Enterome BioScience Company Detail
Table 76. Enterome BioScience Business Overview
Table 77. Enterome BioScience Microbiome Therapeutics Product
Table 78. Enterome BioScience Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Enterome BioScience Recent Development
Table 80. 4D Pharma Company Detail
Table 81. 4D Pharma Business Overview
Table 82. 4D Pharma Microbiome Therapeutics Product
Table 83. 4D Pharma Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 84. 4D Pharma Recent Development
Table 85. Second Genome Company Detail
Table 86. Second Genome Business Overview
Table 87. Second Genome Microbiome Therapeutics Product
Table 88. Second Genome Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 89. Second Genome Recent Development
Table 90. AOBiome Company Detail
Table 91. AOBiome Business Overview
Table 92. AOBiome Microbiome Therapeutics Product
Table 93. AOBiome Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 94. AOBiome Recent Development
Table 95. C3 Jian Company Detail
Table 96. C3 Jian Business Overview
Table 97. C3 Jian Microbiome TherapeuticsProduct
Table 98. C3 Jian Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 99. C3 Jian Recent Development
Table 100. Rebiotix Company Detail
Table 101. Rebiotix Business Overview
Table 102. Rebiotix Microbiome TherapeuticsProduct
Table 103. Rebiotix Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 104. Rebiotix Recent Development
Table 105. MicroBiome Therapeutics LLC Company Detail
Table 106. MicroBiome Therapeutics LLC Business Overview
Table 107. MicroBiome Therapeutics LLC Microbiome TherapeuticsProduct
Table 108. MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 109. MicroBiome Therapeutics LLC Recent Development
Table 110. Metabiomics Company Detail
Table 111. Metabiomics Business Overview
Table 112. Metabiomics Microbiome TherapeuticsProduct
Table 113. Metabiomics Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 114. Metabiomics Recent Development
Table 115. Ritter Pharmaceuticals Company Detail
Table 116. Ritter Pharmaceuticals Business Overview
Table 117. Ritter Pharmaceuticals Microbiome TherapeuticsProduct
Table 118. Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 119. Ritter Pharmaceuticals Recent Development
Table 120. Symberix Company Detail
Table 121. Symberix Business Overview
Table 122. Symberix Microbiome TherapeuticsProduct
Table 123. Symberix Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 124. Symberix Recent Development
Table 125. OpenBiome Company Detail
Table 126. OpenBiome Business Overview
Table 127. OpenBiome Microbiome TherapeuticsProduct
Table 128. OpenBiome Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 129. OpenBiome Recent Development
Table 130. Azitra Company Detail
Table 131. Azitra Business Overview
Table 132. Azitra Microbiome TherapeuticsProduct
Table 133. Azitra Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 134. Azitra Recent Development
Table 135. Symbiotix Biotherapies Company Detail
Table 136. Symbiotix Biotherapies Business Overview
Table 137. Symbiotix Biotherapies Microbiome TherapeuticsProduct
Table 138. Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 139. Symbiotix Biotherapies Recent Development
Table 140. Osel Company Detail
Table 141. Osel Business Overview
Table 142. Osel Microbiome TherapeuticsProduct
Table 143. Osel Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 144. Osel Recent Development
Table 145. Metabogen Company Detail
Table 146. Metabogen Business Overview
Table 147. Metabogen Microbiome TherapeuticsProduct
Table 148. Metabogen Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 149. Metabogen Recent Development
Table 150. Seres Therapeutics Company Information
Table 151. Seres Therapeutics Business Overview
Table 152. Seres Therapeutics Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 153. Seres Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 154. Seres Therapeutics Recent Development
Table 155. Assembly Biosciences Company Information
Table 156. Assembly Biosciences Business Overview
Table 157. Assembly Biosciences Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 158. Assembly Biosciences Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 159. Assembly Biosciences Recent Development
Table 160. Synthetic Biologics Company Information
Table 161. Synthetic Biologics Business Overview
Table 162. Synthetic Biologics Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 163. Synthetic Biologics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 164. Synthetic Biologics Recent Development
Table 165. Interxon Company Information
Table 166. Interxon Business Overview
Table 167. Interxon Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 168. Interxon Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 169. Interxon Recent Development
Table 170. PureTech Company Information
Table 171. PureTech Business Overview
Table 172. PureTech Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 173. PureTech Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 174. PureTech Recent Development
Table 175. Synlogic Company Information
Table 176. Synlogic Business Overview
Table 177. Synlogic Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 178. Synlogic Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 179. Synlogic Recent Development
Table 180. Enterome BioScience Company Information
Table 181. Enterome BioScience Business Overview
Table 182. Enterome BioScience Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 183. Enterome BioScience Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 184. Enterome BioScience Recent Development
Table 185. 4D Pharma Company Information
Table 186. 4D Pharma Business Overview
Table 187. 4D Pharma Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 188. 4D Pharma Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 189. 4D Pharma Recent Development
Table 190. Second Genome Company Information
Table 191. Second Genome Business Overview
Table 192. Second Genome Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 193. Second Genome Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 194. Second Genome Recent Development
Table 195. AOBiome Company Information
Table 196. AOBiome Business Overview
Table 197. AOBiome Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 198. AOBiome Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 199. AOBiome Recent Development
Table 200. C3 Jian Company Information
Table 201. C3 Jian Business Overview
Table 202. C3 Jian Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 203. C3 Jian Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 204. C3 Jian Recent Development
Table 205. Rebiotix Company Information
Table 206. Rebiotix Business Overview
Table 207. Rebiotix Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 208. Rebiotix Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 209. Rebiotix Recent Development
Table 210. MicroBiome Therapeutics LLC Company Information
Table 211. MicroBiome Therapeutics LLC Business Overview
Table 212. MicroBiome Therapeutics LLC Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 213. MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 214. MicroBiome Therapeutics LLC Recent Development
Table 215. Metabiomics Company Information
Table 216. Metabiomics Business Overview
Table 217. Metabiomics Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 218. Metabiomics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 219. Metabiomics Recent Development
Table 220. Ritter Pharmaceuticals Company Information
Table 221. Ritter Pharmaceuticals Business Overview
Table 222. Ritter Pharmaceuticals Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 223. Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 224. Ritter Pharmaceuticals Recent Development
Table 225. Symberix Company Information
Table 226. Symberix Business Overview
Table 227. Symberix Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 228. Symberix Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 229. Symberix Recent Development
Table 230. OpenBiome Company Information
Table 231. OpenBiome Business Overview
Table 232. OpenBiome Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 233. OpenBiome Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 234. OpenBiome Recent Development
Table 235. Azitra Company Information
Table 236. Azitra Business Overview
Table 237. Azitra Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 238. Azitra Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 239. Azitra Recent Development
Table 240. Symbiotix Biotherapies Company Information
Table 241. Symbiotix Biotherapies Business Overview
Table 242. Symbiotix Biotherapies Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 243. Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 244. Symbiotix Biotherapies Recent Development
Table 245. Osel Company Information
Table 246. Osel Business Overview
Table 247. Osel Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 248. Osel Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 249. Osel Recent Development
Table 250. Metabogen Company Information
Table 251. Metabogen Business Overview
Table 252. Metabogen Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 253. Metabogen Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 254. Metabogen Recent Development
Table 255. Authors List of This Report
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Microbiome Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Microbiome Therapeutics Revenue Market Share by Type (2018-2023)
Table 7. Global Microbiome Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Microbiome Therapeutics Revenue Market Share by Type (2024-2029)
Table 9. Global Microbiome Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Microbiome Therapeutics Revenue Market Share by Application (2018-2023)
Table 11. Global Microbiome Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Microbiome Therapeutics Revenue Market Share by Application (2024-2029)
Table 13. Global Microbiome Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Microbiome Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Microbiome Therapeutics Market Share by Region (2018-2023)
Table 16. Global Microbiome Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Microbiome Therapeutics Market Share by Region (2024-2029)
Table 18. Microbiome Therapeutics Market Trends
Table 19. Microbiome Therapeutics Market Drivers
Table 20. Microbiome Therapeutics Market Challenges
Table 21. Microbiome Therapeutics Market Restraints
Table 22. Global Top Microbiome Therapeutics Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Microbiome Therapeutics Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Microbiome Therapeutics Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Microbiome Therapeutics, Headquarters and Area Served
Table 26. Global Microbiome Therapeutics Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Microbiome Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Microbiome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Microbiome Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Microbiome Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 45. Seres Therapeutics Company Detail
Table 46. Seres Therapeutics Business Overview
Table 47. Seres Therapeutics Microbiome Therapeutics Product
Table 48. Seres Therapeutics Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Seres Therapeutics Recent Development
Table 50. Assembly Biosciences Company Detail
Table 51. Assembly Biosciences Business Overview
Table 52. Assembly Biosciences Microbiome Therapeutics Product
Table 53. Assembly Biosciences Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 54. Assembly Biosciences Recent Development
Table 55. Synthetic Biologics Company Detail
Table 56. Synthetic Biologics Business Overview
Table 57. Synthetic Biologics Microbiome Therapeutics Product
Table 58. Synthetic Biologics Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Synthetic Biologics Recent Development
Table 60. Interxon Company Detail
Table 61. Interxon Business Overview
Table 62. Interxon Microbiome Therapeutics Product
Table 63. Interxon Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Interxon Recent Development
Table 65. PureTech Company Detail
Table 66. PureTech Business Overview
Table 67. PureTech Microbiome Therapeutics Product
Table 68. PureTech Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 69. PureTech Recent Development
Table 70. Synlogic Company Detail
Table 71. Synlogic Business Overview
Table 72. Synlogic Microbiome Therapeutics Product
Table 73. Synlogic Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Synlogic Recent Development
Table 75. Enterome BioScience Company Detail
Table 76. Enterome BioScience Business Overview
Table 77. Enterome BioScience Microbiome Therapeutics Product
Table 78. Enterome BioScience Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Enterome BioScience Recent Development
Table 80. 4D Pharma Company Detail
Table 81. 4D Pharma Business Overview
Table 82. 4D Pharma Microbiome Therapeutics Product
Table 83. 4D Pharma Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 84. 4D Pharma Recent Development
Table 85. Second Genome Company Detail
Table 86. Second Genome Business Overview
Table 87. Second Genome Microbiome Therapeutics Product
Table 88. Second Genome Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 89. Second Genome Recent Development
Table 90. AOBiome Company Detail
Table 91. AOBiome Business Overview
Table 92. AOBiome Microbiome Therapeutics Product
Table 93. AOBiome Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 94. AOBiome Recent Development
Table 95. C3 Jian Company Detail
Table 96. C3 Jian Business Overview
Table 97. C3 Jian Microbiome TherapeuticsProduct
Table 98. C3 Jian Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 99. C3 Jian Recent Development
Table 100. Rebiotix Company Detail
Table 101. Rebiotix Business Overview
Table 102. Rebiotix Microbiome TherapeuticsProduct
Table 103. Rebiotix Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 104. Rebiotix Recent Development
Table 105. MicroBiome Therapeutics LLC Company Detail
Table 106. MicroBiome Therapeutics LLC Business Overview
Table 107. MicroBiome Therapeutics LLC Microbiome TherapeuticsProduct
Table 108. MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 109. MicroBiome Therapeutics LLC Recent Development
Table 110. Metabiomics Company Detail
Table 111. Metabiomics Business Overview
Table 112. Metabiomics Microbiome TherapeuticsProduct
Table 113. Metabiomics Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 114. Metabiomics Recent Development
Table 115. Ritter Pharmaceuticals Company Detail
Table 116. Ritter Pharmaceuticals Business Overview
Table 117. Ritter Pharmaceuticals Microbiome TherapeuticsProduct
Table 118. Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 119. Ritter Pharmaceuticals Recent Development
Table 120. Symberix Company Detail
Table 121. Symberix Business Overview
Table 122. Symberix Microbiome TherapeuticsProduct
Table 123. Symberix Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 124. Symberix Recent Development
Table 125. OpenBiome Company Detail
Table 126. OpenBiome Business Overview
Table 127. OpenBiome Microbiome TherapeuticsProduct
Table 128. OpenBiome Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 129. OpenBiome Recent Development
Table 130. Azitra Company Detail
Table 131. Azitra Business Overview
Table 132. Azitra Microbiome TherapeuticsProduct
Table 133. Azitra Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 134. Azitra Recent Development
Table 135. Symbiotix Biotherapies Company Detail
Table 136. Symbiotix Biotherapies Business Overview
Table 137. Symbiotix Biotherapies Microbiome TherapeuticsProduct
Table 138. Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 139. Symbiotix Biotherapies Recent Development
Table 140. Osel Company Detail
Table 141. Osel Business Overview
Table 142. Osel Microbiome TherapeuticsProduct
Table 143. Osel Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 144. Osel Recent Development
Table 145. Metabogen Company Detail
Table 146. Metabogen Business Overview
Table 147. Metabogen Microbiome TherapeuticsProduct
Table 148. Metabogen Revenue in Microbiome Therapeutics Business (2017-2022) & (US$ Million)
Table 149. Metabogen Recent Development
Table 150. Seres Therapeutics Company Information
Table 151. Seres Therapeutics Business Overview
Table 152. Seres Therapeutics Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 153. Seres Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 154. Seres Therapeutics Recent Development
Table 155. Assembly Biosciences Company Information
Table 156. Assembly Biosciences Business Overview
Table 157. Assembly Biosciences Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 158. Assembly Biosciences Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 159. Assembly Biosciences Recent Development
Table 160. Synthetic Biologics Company Information
Table 161. Synthetic Biologics Business Overview
Table 162. Synthetic Biologics Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 163. Synthetic Biologics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 164. Synthetic Biologics Recent Development
Table 165. Interxon Company Information
Table 166. Interxon Business Overview
Table 167. Interxon Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 168. Interxon Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 169. Interxon Recent Development
Table 170. PureTech Company Information
Table 171. PureTech Business Overview
Table 172. PureTech Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 173. PureTech Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 174. PureTech Recent Development
Table 175. Synlogic Company Information
Table 176. Synlogic Business Overview
Table 177. Synlogic Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 178. Synlogic Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 179. Synlogic Recent Development
Table 180. Enterome BioScience Company Information
Table 181. Enterome BioScience Business Overview
Table 182. Enterome BioScience Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 183. Enterome BioScience Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 184. Enterome BioScience Recent Development
Table 185. 4D Pharma Company Information
Table 186. 4D Pharma Business Overview
Table 187. 4D Pharma Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 188. 4D Pharma Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 189. 4D Pharma Recent Development
Table 190. Second Genome Company Information
Table 191. Second Genome Business Overview
Table 192. Second Genome Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 193. Second Genome Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 194. Second Genome Recent Development
Table 195. AOBiome Company Information
Table 196. AOBiome Business Overview
Table 197. AOBiome Microbiome Therapeutics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 198. AOBiome Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 199. AOBiome Recent Development
Table 200. C3 Jian Company Information
Table 201. C3 Jian Business Overview
Table 202. C3 Jian Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 203. C3 Jian Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 204. C3 Jian Recent Development
Table 205. Rebiotix Company Information
Table 206. Rebiotix Business Overview
Table 207. Rebiotix Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 208. Rebiotix Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 209. Rebiotix Recent Development
Table 210. MicroBiome Therapeutics LLC Company Information
Table 211. MicroBiome Therapeutics LLC Business Overview
Table 212. MicroBiome Therapeutics LLC Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 213. MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 214. MicroBiome Therapeutics LLC Recent Development
Table 215. Metabiomics Company Information
Table 216. Metabiomics Business Overview
Table 217. Metabiomics Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 218. Metabiomics Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 219. Metabiomics Recent Development
Table 220. Ritter Pharmaceuticals Company Information
Table 221. Ritter Pharmaceuticals Business Overview
Table 222. Ritter Pharmaceuticals Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 223. Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 224. Ritter Pharmaceuticals Recent Development
Table 225. Symberix Company Information
Table 226. Symberix Business Overview
Table 227. Symberix Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 228. Symberix Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 229. Symberix Recent Development
Table 230. OpenBiome Company Information
Table 231. OpenBiome Business Overview
Table 232. OpenBiome Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 233. OpenBiome Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 234. OpenBiome Recent Development
Table 235. Azitra Company Information
Table 236. Azitra Business Overview
Table 237. Azitra Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 238. Azitra Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 239. Azitra Recent Development
Table 240. Symbiotix Biotherapies Company Information
Table 241. Symbiotix Biotherapies Business Overview
Table 242. Symbiotix Biotherapies Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 243. Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 244. Symbiotix Biotherapies Recent Development
Table 245. Osel Company Information
Table 246. Osel Business Overview
Table 247. Osel Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 248. Osel Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 249. Osel Recent Development
Table 250. Metabogen Company Information
Table 251. Metabogen Business Overview
Table 252. Metabogen Microbiome TherapeuticsRevenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million)
Table 253. Metabogen Revenue in Microbiome Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 254. Metabogen Recent Development
Table 255. Authors List of This Report
LIST OF FIGURES
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Microbiome Therapeutics Product Picture
Figure 5. Global Microbiome Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Microbiome Therapeutics Market Share by Type: 2022 VS 2029
Figure 7. Upper GIT Product Picture
Figure 8. Lower GIT Product Picture
Figure 9. Global Microbiome Therapeutics Market Size by Application (2023-2029) & (US$ Million)
Figure 10. Global Microbiome Therapeutics Market Share by Application: 2022 VS 2029
Figure 11. C. difficile Infection (CDI) Product Picture
Figure 12. Inflammatory Bowel Disease (IBD) Product Picture
Figure 13. Orphan Drug Product Picture
Figure 14. Immuno-oncology Product Picture
Figure 15. Others Product Picture
Figure 16. Global Microbiome Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Microbiome Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Microbiome Therapeutics Market Share by Region: 2022 VS 2029
Figure 19. Global Microbiome Therapeutics Market Share by Players in 2022
Figure 20. Global Microbiome Therapeutics Players, Date of Enter into This Industry
Figure 21. Global Top 5 and 10 Microbiome Therapeutics Players Market Share by Revenue in 2022
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 23. North America Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Microbiome Therapeutics Market Share by Country (2018-2029)
Figure 25. United States Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Microbiome Therapeutics Market Share by Country (2018-2029)
Figure 29. Germany Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Microbiome Therapeutics Market Share by Country (2018-2029)
Figure 37. China Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Japan Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. South Korea Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Southeast Asia Microbi
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Microbiome Therapeutics Product Picture
Figure 5. Global Microbiome Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Microbiome Therapeutics Market Share by Type: 2022 VS 2029
Figure 7. Upper GIT Product Picture
Figure 8. Lower GIT Product Picture
Figure 9. Global Microbiome Therapeutics Market Size by Application (2023-2029) & (US$ Million)
Figure 10. Global Microbiome Therapeutics Market Share by Application: 2022 VS 2029
Figure 11. C. difficile Infection (CDI) Product Picture
Figure 12. Inflammatory Bowel Disease (IBD) Product Picture
Figure 13. Orphan Drug Product Picture
Figure 14. Immuno-oncology Product Picture
Figure 15. Others Product Picture
Figure 16. Global Microbiome Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Microbiome Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Microbiome Therapeutics Market Share by Region: 2022 VS 2029
Figure 19. Global Microbiome Therapeutics Market Share by Players in 2022
Figure 20. Global Microbiome Therapeutics Players, Date of Enter into This Industry
Figure 21. Global Top 5 and 10 Microbiome Therapeutics Players Market Share by Revenue in 2022
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 23. North America Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Microbiome Therapeutics Market Share by Country (2018-2029)
Figure 25. United States Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Microbiome Therapeutics Market Share by Country (2018-2029)
Figure 29. Germany Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Microbiome Therapeutics Market Share by Country (2018-2029)
Figure 37. China Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Japan Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. South Korea Microbiome Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Southeast Asia Microbi
